Ribosomal Dysregulation in Metastatic Laryngeal Squamous Cell Carcinoma: Proteomic Insights and CX-5461's Therapeutic Promise

Overview

Journal Toxics

Date 2024 May 24

PMID 38787142

Authors

Miao Gao

Ting Liu

Kairui Hu

Songling Chen

Shixin Wang

Di Gan

Zhihan Li

Xiaohuang Lin

Affiliations

Soon will be listed here.

Abstract

One of the main barriers to the successful treatment of laryngeal squamous cell carcinoma (LSCC) is postoperative progression, primarily due to tumor cell metastasis. To systematically investigate the molecular characteristics and potential mechanisms underlying the metastasis in laryngeal cancer, we carried out a TMT-based proteomic analysis of both cancerous and adjacent non-cancerous tissues from 10 LSCC patients with lymph node metastasis (LNM) and 10 without. A total of 5545 proteins were quantified across all samples. We identified 57 proteins that were downregulated in LSCC with LNM, which were enriched in cell adhesion pathways, and 69 upregulated proteins predominantly enriched in protein production pathways. Importantly, our data revealed a strong correlation between increased ribosomal activity and the presence of LNM, as 18 ribosomal subunit proteins were found to be upregulated, with RPS10 and RPL24 being the most significantly overexpressed. The potential of ribosomal proteins, including RPS10 and RPL24, as biomarkers for LSCC with LNM was confirmed in external validation samples (six with LNM and six without LNM) using Western blotting and immunohistochemistry. Furthermore, we have confirmed that the RNA polymerase I inhibitor CX-5461, which impedes ribosome biogenesis in LSCC, also decreases the expression of RPS10, RPL24, and RPS26. In vitro experiments have revealed that CX-5461 moderately reduces cell viability, while it significantly inhibits the invasion and migration of LSCC cells. It can enhance the expression of the epithelial marker CDH1 and suppress the expression of the mesenchymal markers CDH2, VIM, and FN at a dose that does not affect cell viability. Our study broadens the scope of the proteomic data on laryngeal cancer and suggests that ribosome targeting could be a supplementary therapeutic strategy for metastatic LSCC.

Citing Articles

SNF2L maintains glutathione homeostasis by initiating SLC7A11 transcription through chromatin remodeling.

Zhang J, Gao Z, Yang Y, Li Z, Wu B, Fan C Cell Death Dis. 2024; 15(11):820.

PMID: 39532848 PMC: 11557580. DOI: 10.1038/s41419-024-07221-4.

References

Sherman B, Hao M, Qiu J, Jiao X, Baseler M, Lane H . DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-W221. PMC: 9252805. DOI: 10.1093/nar/gkac194. View

White R . RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol. 2005; 6(1):69-78. DOI: 10.1038/nrm1551. View

Babaian A, Rothe K, Girodat D, Minia I, Djondovic S, Milek M . Loss of macpΨ Ribosomal RNA Modification Is a Major Feature of Cancer. Cell Rep. 2020; 31(5):107611. DOI: 10.1016/j.celrep.2020.107611. View

Kim H, Maiti P, Barrientos A . Mitochondrial ribosomes in cancer. Semin Cancer Biol. 2017; 47:67-81. PMC: 5662495. DOI: 10.1016/j.semcancer.2017.04.004. View

Li C, Sun Y, Yu G, Cui J, Lou Z, Zhang H . Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell. 2020; 38(5):734-747.e9. DOI: 10.1016/j.ccell.2020.08.002. View

Dermit M, Dodel M, Lee F, Azman M, Schwenzer H, Jones J . Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells. Dev Cell. 2020; 55(3):298-313.e10. PMC: 7660134. DOI: 10.1016/j.devcel.2020.10.006. View

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

Cossu A, Mosca L, Zappavigna S, Misso G, Bocchetti M, De Micco F . Long Non-coding RNAs as Important Biomarkers in Laryngeal Cancer and Other Head and Neck Tumours. Int J Mol Sci. 2019; 20(14). PMC: 6678449. DOI: 10.3390/ijms20143444. View

Wang Z, Li J, Long X, Jiao L, Zhou M, Wu K . MRPS16 facilitates tumor progression via the PI3K/AKT/Snail signaling axis. J Cancer. 2020; 11(8):2032-2043. PMC: 7052926. DOI: 10.7150/jca.39671. View

10.

Karaman S, Detmar M . Mechanisms of lymphatic metastasis. J Clin Invest. 2014; 124(3):922-8. PMC: 3938272. DOI: 10.1172/JCI71606. View

11.

Karayel O, Virreira Winter S, Padmanabhan S, Kuras Y, Vu D, Tuncali I . Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson's disease. Cell Rep Med. 2022; 3(6):100661. PMC: 9245058. DOI: 10.1016/j.xcrm.2022.100661. View

12.

Drygin D, Lin A, Bliesath J, Ho C, OBrien S, Proffitt C . Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2010; 71(4):1418-30. DOI: 10.1158/0008-5472.CAN-10-1728. View

13.

Park B, Chiosea S, Grandis J . Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomark. 2011; 9(1-6):325-39. PMC: 3409637. DOI: 10.3233/CBM-2011-0163. View

14.

van Riggelen J, Yetil A, Felsher D . MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010; 10(4):301-9. DOI: 10.1038/nrc2819. View

15.

Ming C, Bai X, Zhao L, Yu D, Wang X, Wu Y . RPL24 as a potential prognostic biomarker for cervical cancer treated by Cisplatin and concurrent chemoradiotherapy. Front Oncol. 2023; 13:1131803. PMC: 10619668. DOI: 10.3389/fonc.2023.1131803. View

16.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

17.

Mossmann D, Park S, Hall M . mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018; 18(12):744-757. DOI: 10.1038/s41568-018-0074-8. View

18.

Sanij E, Hannan K, Xuan J, Yan S, Ahern J, Trigos A . CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat Commun. 2020; 11(1):2641. PMC: 7251123. DOI: 10.1038/s41467-020-16393-4. View

19.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

20.

Pelletier J, Thomas G, Volarevic S . Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2017; 18(1):51-63. DOI: 10.1038/nrc.2017.104. View